Relmada Therapeutics (RLMD) Return on Assets (2013 - 2026)

Relmada Therapeutics (RLMD) has 14 years of Return on Assets data on file, last reported at 0.01% in Q1 2026.

• On a quarterly basis, Return on Assets rose 2.0% year-over-year to 0.01% in Q1 2026; TTM through Mar 2026 was 0.01%, a 2.0% increase from a year earlier, with the FY2025 full-year figure at 0.01%, changed 0.0% from the prior year.
• Return on Assets for Q1 2026 stood at 0.01%, up from 0.01% in the prior quarter.
• Over the last five years, Return on Assets for RLMD reached as high as 0.01% in Q1 2026 and fell as low as 0.03% in Q3 2025.
• Historically, Return on Assets has averaged 0.01% across 5 years, with a median of 0.01% in 2022.
• Across the five-year window, Return on Assets slipped 2 bps in 2025 and grew 2 bps in 2026, its largest moves.
• Year by year, Return on Assets stood at 0.01% in 2022, then decreased by 0 bps to 0.01% in 2023, then plunged by 99 bps to 0.02% in 2024, then jumped by 44 bps to 0.01% in 2025, then soared by 45 bps to 0.01% in 2026.
• Per Business Quant data, the three most recent Return on Assets figures were 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.03% in Q3 2025.